Key: ALL- Acute lymphocytic leukemia AML- Acute myeloid leukemia

CLL- Chronic lymphocytic leukemia CML- Chronic myeloid leukemia

BF- bulky lymphadenopathy (refractory CLL)
FA- fludaribine and alemetuzumab (refractory CLL)
NCBI- National Center for Biotechnology Information
AACR- American Association for Cancer Research
ASH- American Study of Hematology
STC- Stem cell transplantation
JCO- Journal of Clinical Oncology
ASCO- American Society of Clinical Oncology
CR- complete remission
 Document Name & Source Improved leukemia-free survival…; American Study of Ofatumumab As Single-Agent CD20 Immunotherapy…; JCO
Hematology
Treatment Type Immunotherapy Immunotherapy
Document Type Study Study
Authors/Creators/Publisher ASH NCBI
s
Document Info (ex. Study Of 320 patients with AML, 261 achieved complete FA- 57%
Results) remission after treatment BF-48%
Possible Faults (ex. Bias) - -
Link/Citation http://www.bloodjournal.org/content/108/1/88.short?sso https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979101
-checked=true /

Document Adoptive Immunotherapy of Full Haplotype-Mismatched Hematopoietic SCT; JCO

Name & Leukemia…; Institut de
Source Cancérologie et
d’Immunogénétique
Treatment Immunotherapy SCT
Type
Document Study Study
Type
Authors/Crea AACR ASCO
tors/Publishe
rs
Document Trials were conducted in which AML- of 67 treated patients, 19 achieved CR the first time, 25 relapsed
Info (ex. mice were given different types ALL- of 37 treated patients, 14 achieved CR the first time, 13 relapsed
Study of leukemia and treated with
Results) immunotherapy. The trials were
not very successful
Possible Study is not clear about starting -
Faults (ex. sample sizes
Bias)
Link/Citation http://cancerres.aacrjournals.or https://s3.amazonaws.com/academia.edu.documents/45036617/3447.full.pdf?AWSAccess
g/content/canres/25/9_Part_1/1 KeyId=AKIAIWOWYYGZ2Y53UL3A&Expires=1525967434&Signature=KAv03gbyiAPPoLvt0pIf
525.full.pdf bTlKjcE%3D&response-content-disposition=inline%3B%20filename%3DFull_Haplotype-
Mismatched_Hematopoietic.pdf

Document Name & Source Allogeneic SCT provides durable disease control in poor-risk CLL: American
Study of Hematology
Treatment Type SCT
Document Type Study
Authors/Creators/Publishers ASH
Document Info (ex. Study Results) Event free survival is 52%
Possible Faults (ex. Bias) -
Link/Citation http://www.bloodjournal.org/content/bloodjournal/early/2010/07/01/blood-
2010-03-275420.full.pdf?sso-checked=true

Sources:
http://www.bloodjournal.org/content/108/1/88.short?sso-checked=true

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979101/

http://cancerres.aacrjournals.org/content/canres/25/9_Part_1/1525.full.pdf
https://s3.amazonaws.com/academia.edu.documents/45036617/3447.full.pdf?AWSAccessKeyId=AKIAIWOWYYGZ2Y53UL3A&Expire
s=1525967434&Signature=KAv03gbyiAPPoLvt0pIfbTlKjcE%3D&response-content-
disposition=inline%3B%20filename%3DFull_Haplotype-Mismatched_Hematopoietic.pdf

http://www.bloodjournal.org/content/bloodjournal/early/2010/07/01/blood-2010-03-275420.full.pdf?sso-checked=true